Abstract B82: Identification of tumor neoantigens for combination therapy in murine tumor models
Sign Up to like & getrecommendations! Published in 2018 at "Cancer immunology research"
DOI: 10.1158/2326-6074.tumimm17-b82
Abstract: The adoption of anti-CTLA-4 and anti-PD-1/PD-L1 blockade has dramatically changed the treatment approaches in multiple cancer types, and has demonstrated the power of the immune system to control the outgrowth of neoplastic lesions. Accumulating evidence… read more here.
Keywords: combination; nonsynonymous mutations; tumor neoantigens; therapy ... See more keywords
Prediction of the Effects of Nonsynonymous Variants on SARS-CoV-2 Proteins.
Sign Up to like & getrecommendations! Published in 2022 at "F1000Research"
DOI: 10.12688/f1000research.72904.1
Abstract: Background: SARS-CoV-2 virus is a highly transmissible pathogen that causes COVID-19. The outbreak originated in Wuhan, China in December 2019. A number of nonsynonymous mutations located at different SARS-CoV-2 proteins have been reported by multiple studies. However, there are limited computational studies on the biological impacts of these mutations on the structure and… read more here.
Keywords: nonsynonymous mutations; prediction; cov proteins; orf1a nsp5 ... See more keywords
Prediction of the effects of the top 10 nonsynonymous variants from 30229 SARS-CoV-2 strains on their proteins
Sign Up to like & getrecommendations! Published in 2022 at "F1000Research"
DOI: 10.12688/f1000research.72904.2
Abstract: Background: SARS-CoV-2 virus is a highly transmissible pathogen that causes COVID-19. The outbreak originated in Wuhan, China in December 2019. A number of nonsynonymous mutations located at different SARS-CoV-2 proteins have been reported by multiple… read more here.
Keywords: top nonsynonymous; effects top; nonsynonymous mutations; cov proteins ... See more keywords